secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-311294
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction
--------------------------------------------------------------------------------

- Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).
- Stockholders approved proposal to issue New PIPE Shares and Pre-Funded Warrant under Sept 28 securities purchase agreement (2,049,724 For).
- Stockholders approved adjournment proposal (2,058,277 For).
- Initial MVID proof-of-concept trial shows crofelemer can reduce total parenteral support by up to 37% in infants with microvillus inclusion disease.
- Company met with FDA on Oct 2, 2025 for advice on expedited approval pathway for crofelemer for MVID; no approved treatments exist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312525311294/0001193125-25-311294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312525311294/jagx-20251208.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-311294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer